Sales of antiarrhythmic medicines in Spain have shown a declining trend over the past decade. From 2013 to 2016, sales remained stable at 0.3 units. However, starting in 2017, sales began to decline, reaching 0.1 units by 2019, and have remained at that level through 2023. Year-on-year variation shows significant drops in 2017 (-33.33%) and 2019 (-50%), with a stagnant trend from 2020 onwards. The Compound Annual Growth Rate (CAGR) over the last five years has been -12.94%, indicating a sustained downward trend.

Looking forward, the forecast for sales between 2024 and 2028 is stable, with no expected growth or decline, and a forecasted 5-year CAGR of 0%. This plateau suggests the market has reached a stable low point.

Future trends to watch for include:

Technological advancements in treatment options which may impact the demand for traditional antiarrhythmic medicines.
Changes in healthcare policies or pharmaceutical pricing regulations that could affect market dynamics.
Emergence of new competitors or alternative therapies that might influence the sales volume.
Public health trends and the incidence of conditions requiring antiarrhythmic medications.